The diagnosis of myelodysplastic neoplasms (MDS) requires examination of the bone marrow for morphologic evidence of dysplasia. We sought to determine if a self-supervised learning (SSL) AI image analysis approach may be utilized to reliably distinguish MDS from its clinically relevant mimics using bone marrow biopsies (BMBx). Whole slide images (WSIs) of H&E- and reticulin-stained BMBx sections from 243 unique patients (89 MDS, 55 non-MDS cytopenic controls [NMCC], and 99 negative control [NC] cases) were segmented into tiles and analyzed. These tiles were then processed using the Barlow Twins SSL model to generate histomorphologic phenotype clusters (HPCs). Review of the HPCs revealed the clusters enriched in MDS captured known histopathologic features of MDS including hypercellularity, dysplastic and clustered megakaryocytes, increased immature hematopoietic cells, increased vascularity, fibrosis, and cell streaming patterns. Assessment of 95 MDS BMBx images from a second institution showed consistent HPC enrichment patterns, validating the robustness of the model. The trained ensemble model using H&E- and reticulin-stained slides distinguished MDS from NCs with an AUC of 0.89, and from age-matched, NMCCs with an AUC of 0.84. These findings demonstrate the potential of SSL approaches to capture diagnostically relevant morphologic patterns and to improve the reproducibility of MDS diagnosis.

SL: Consultancy/Honoraria: Recordati, Daiichi-Sankyo, AlphaSights, Gerson Lehrman Group, Arima Genomics, Ground Truth Labs, Qiagen, Servier, Syndax, Kura, AbbVie, Cogent, Tempus AI, Caris Diagnostics; Stock Ownership: AbbVie.

This study was funded by NIH/NCI (R01CA249054).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of NYU Grossman School of Medicine gave ethical approval for this work (IRB# i22-00178).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.